The pathogenesis of prostate cancer: from molecular to metabolic alterations
✍ Scribed by Elisa Benedettini; Paul Nguyen; Massimo Loda
- Publisher
- Elsevier
- Year
- 2008
- Tongue
- English
- Weight
- 729 KB
- Volume
- 14
- Category
- Article
- ISSN
- 1756-2317
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract 3,3′,5,5′‐ And 2,2′,6,6′‐tetrafluoro‐substituted 1‐[(1,1′‐biphenyl]‐4‐yl)methyl]‐1__H__‐imidazoles were synthesized as inhibitors of 17__α__‐hydroxylase‐C17,20‐lyase (P450 17, CYP 17). P450 17 is the key enzyme of androgen biosynthesis. Its inhibition is a novel therapeutic approach for
Prostate cancer has a propensity to metastasize to the bone. Currently the only effective systemic treatment for these patients is androgen ablation therapy. However, the tumor will invariably progress to an androgen-independent stage and the patient will succumb to his disease within approximately
## Abstract It is widely known that death receptor Fas‐dependent apoptotic signals are associated with development of prostate cancer, but the key pathways involved in sensitivity to the apoptosis remain unclear. Here we investigated the molecular mechanism by which 2‐methoxyestradiol (2‐ME) effect
## Abstract The gluconeogenic phosphoenolpyruvate (PEP) carboxykinase is active in __Escherichia coli__ during its growth on glucose. The present study investigated the influence of growth rates and PEP carboxykinase knockout on the anaplerotic fluxes in __E. coli__. The intracellular fluxes were d